文献速递淋巴瘤

停止对无症状低危慢性淋巴细胞白血病患者进行专科随访是可行且安全的

It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

研究比较了112例经临床评估后停止专科随访与88例继续专科随访的低至中危无症状慢性淋巴细胞白血病患者的3年结局:两组总生存相似(87% vs 80%,P=0.16),停止随访组就诊次数更少、首次感染时间更长、3年首次治疗率更低(4% vs 23%,P<0.0001)。

要点

  • 停止专科随访组3年总生存87%,继续随访组80%,两组相似(P=0.16)。
  • 停止随访组每患者年就诊次数中位数0.7次,继续随访组4.3次(P<0.0001)。
  • 停止随访组3年首次治疗率4%,继续随访组23%(P<0.0001)。

核心结论

  • 对于经全面临床评估后CLL-IPI和CLL-WONT评分为低至中危的慢性淋巴细胞白血病患者,停止专科随访是可行且安全的。

研究设计与样本

  • 研究比较了经临床评估选择停止专科随访的112例患者与选择继续专科随访的88例患者的3年临床结局。
  • 研究对象为无症状、CLL-IPI和CLL-WONT评分为低至中危、享有全民医疗保障的慢性淋巴细胞白血病患者。
  • 当地医院管理层为优化医疗资源配置,实施了停止此类患者专科随访的措施。

主要发现

  • 停止随访组患者年龄更大,但其他方面风险低于继续随访组。
  • 停止随访组与继续随访组3年总生存率分别为87%和80%(P=0.16),两组相似。
  • 停止随访组每患者年就诊次数中位数为0.7次,继续随访组为4.3次(P<0.0001)。
  • 停止随访组首次感染时间更长(P=0.035),住院抗菌治疗时间中位数为4天,继续随访组为12天(P=0.026)。
  • 6例患者中1例被重新转诊,其中4例符合国际慢性淋巴细胞白血病工作组(iwCLL)需要治疗的标准;停止随访组3年首次治疗率为4%,继续随访组为23%(P<0.0001)。

临床怎么用

  • 作者认为,对于经全面临床评估后CLL-IPI和CLL-WONT评分为低至中危的慢性淋巴细胞白血病患者,停止专科随访是可行且安全的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately half of patients with chronic lymphocytic leukemia (CLL) will never require treatment; nonetheless, they are recommended life-long specialized follow-up (sFU). To prioritize health care resources, local hospital management implemented ending sFU in asymptomatic patients with CLL International Prognostic Index (CLL-IPI) and CLL without need of treatment (CLL-WONT) low-to-intermediate risk, who were covered by universal health care. To evaluate the feasibility and safety of ending sFU, we investigated 3-year clinical outcomes among 112 patients selected by clinical assessment to end sFU as compared with 88 patients selected to continue sFU. Patients who ended sFU were older, but otherwise lower risk compared with patients continuing sFU. Overall survival (OS) was similar in patients ending and continuing sFU (3-year OS, 87% and 80%, respectively; P = .16). Hospital visits per patient-year were lower (median 0.7 vs 4.3, P < .0001) and time to first infection was longer (P = .035) in patients ending sFU compared with those who continued sFU, including shorter in-hospital antimicrobial treatment (median 4 vs 12 days, respectively; P = .026). Finally, 1 in 6 patients were rereferred, including 4 patients meeting international workshop on CLL criteria for need of treatment. This also resulted in a lower 3-year first treatment rate for patients ending sFU compared with patients continuing sFU (4% vs 23%, respectively; P < .0001). In conclusion, it is feasible and safe to end sFU for patients with CLL who have low-to-intermediate risk CLL-IPI and CLL-WONT scores upon thorough clinical evaluation before ending sFU.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Brieghel C, da Cunha-Bang C, Mourek J, et al. It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia. Blood Adv. 2024. PMID: 38429090. doi:10.1182/bloodadvances.2023012382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。